President Trump may think top drugmakers are ready to step up with price cuts, but Pfizer, for one, is going the other way instead. The pharma giant hiked prices on 100 drugs, including one of its biggest sellers, as of
read moreRecordati has finally sealed a sale. Private equity player CVC Capital Partners agreed to drop €3.03 billion ($3.5 billion) on a 51.8% controlling stake, aiming to use its own connections to help beef up Recordati’s orphan and specialty care business.
read moreThe National Institute for Health and Care Excellence has concluded that Roche’s Ocrevus should not be funded on the NHS for the treatment of primary progressive multiple sclerosis (PPMS) in adults. More: NICE ‘no’ for Roche’s Ocrevus in primary progressive
read moreRoche has unveiled data showing that a combination of Tecentriq and Abraxane significantly slashed the risk of disease worsening or death in some breast cancer patients. More: Roche gearing up to file Tecentriq for breast cancer Source: News
read moreThe stage has been set for approval of the first chimeric antigen T-cell therapies (CAR-T) in Europe, after Novartis’ Kymriah and Gilead’s Yescarta both won backing from the Committee for Medicinal Products for Human Use (CHMP). More: CAR-T therapies leap
read moreNHS England’s flagship vanguard programme has not delivered the depth and scale of transformed services originally aimed for, according to an investigation by the National Audit Office (NAO). More: NHS ‘Vanguards’ failing to reach potential, finds NAO Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals